Friday, July 1, 2022
HomeNews3 supercharged growth stocks that can turn $250,000 into $1 million by...

3 supercharged growth stocks that can turn $250,000 into $1 million by 2030


OWhether you’re a newbie or a seasoned investor, you’ve received a not-so-subtle reminder over the past few months that stock market corrections are a normal and inevitable part of the investment cycle. Since the start of the year, the broad base S&P500 and widely followed Dow Jones Industrial Average dipped into official corrective territory (down at least 10%), while tech focused Nasdaq Compound briefly fell into a bear market.

There is no doubt that sharp declines in indices can be disconcerting. But it is important to recognize that stock market corrections rarely last long. Additionally, every crash and correction in history has proven to be an ideal buying opportunity for patient investors. Buying high-quality stocks during pullbacks and allowing your investment thesis to materialize over time is a lucrative strategy.

Image source: Getty Images.

That being said, the recent market correction has made three supercharged growth stocks particularly attractive. If you were to invest $250,000 in these companies, they have all the tools necessary to make you a millionaire by 2030.

Teladoc Health

The first supercharged growth stock that should reward patient investors handsomely by the turn of the decade is the telehealth giant Teladoc Health (NYSE: TDOC).

Teladoc is one of dozens of high-growth companies that benefited enormously from the early stages of the COVID-19 pandemic, but have since been rocked by valuation and growth issues. It also paid a price (literally and figuratively) for its acquisition of Livongo Health in late 2020, which resulted in bigger than expected losses in 2020 and 2021.

Despite these near-term challenges, there is no suggestion that Teladoc’s direction has strayed or that its competitive advantages have faded a bit. For example, the company’s sales increased by an annual average of 74% between 2013 and 2019 (before the pandemic). In the wake of the pandemic, sales growth is expected to continue to exceed 20% on an annual basis.

What Teladoc’s sales growth demonstrates is that we are seeing a shift in the way personalized care is delivered. While virtual visits may not be feasible for every appointment, Teladoc’s platform offers patients and physicians a powerful tool to improve overall outcomes. Virtual visits are more convenient for patients and they allow doctors to easily keep tabs on patients with chronic conditions. The end result should be less money in the pockets of health insurers (so they will favor telemedicine visits).

Although the acquisition of Livongo was, in retrospect, prohibitively expensive, the deal nevertheless gives Teladoc the ability to cross-sell its solutions and address the needs of people with chronic conditions who would benefit most from its personalized care. Additionally, the one-time costs associated with this agreement will not negatively impact Teladoc’s results in 2022 and beyond.

After a nearly 80% retracement, Teladoc shares can now be bought for about five times last year’s sales. But if Teladoc continues to grow at 20% per year, it will generate over $10.5 billion in sales by 2030. That would give it a price-to-sales ratio of 1. In other words, if Teladoc simply maintains its current price – at the sell multiple, investors should have no problem turning $250,000 into $1 million.

Image source: Getty Images.

Jushi Holdings

Another supercharged growth stock with all the tools and intangibles needed to quadruple investors’ money over the next eight years is the marijuana stock. Jushi Holdings (OTC: JUSHF).

Few industries have been more universally hated by the investing community over the past year than US stocks. The expectation with a Democrat-led Congress and Joe Biden in the Oval Office was that federal legalization, or at the very least cannabis banking reforms, would become a reality. So far, these expectations have not materialized and investors are clearly not satisfied.

However, federal legalization is not a necessity for large-scale multi-state operators (MSOs) like Jushi to thrive. With roughly three quarters of all US states legalizing weed to some degree, there is more than enough organic opportunity for these businesses to grow rapidly and turn a profit.

Jushi is a relatively small player among the most well-known MSOs. At the start of this month, it had 29 operating clinics in half a dozen states, with plans to expand its portfolio to about 40 operating clinics by the end of 2022.

What makes this company so unique is that it focuses on limited license markets, such as Virginia, Illinois, Pennsylvania, and Massachusetts. Limited license states deliberately limit the total number of retail licenses issued, as well as to individual businesses. It’s a way to ensure that smaller players like Jushi have a fair chance to grow their brand(s) and build audience loyalty without being crushed by a deeper-pocketed MSO.

Interestingly, however, Jushi hasn’t been afraid to pull the acquisition trigger. It completed the NuLeaf takeover just two weeks ago, which will strengthen its vertically integrated presence in Nevada. It also entered the highly lucrative California pot market last year.

But perhaps the best thing about Jushi is that management aligns its portfolio with that of its shareholders. About $45 million of the first $250 million in capital raised came from insiders and executives. We also saw CEO Jim Cacioppo buy shares of the company on the open market. When leaders have skin in the game, good things often happen.

Mini boxes and mini hand basket on a tablet and an open laptop.

Image source: Getty Images.

Sea Limited

A third supercharged growth stock that can turn an initial $250,000 investment into a million by 2030 is based in Singapore Sea Limited (NYSE:SE).

Like Teladoc, Sea has been crashed in recent months. A forecast calling for slower growth in 2022 did not sit well with investors who expect eye-popping revenue growth from the company. Sea also noted that it could be until 2025 before two of its key segments can “substantially self-fund their long-term growth.” That’s a bit longer than some optimists expected.

While short-term losses aren’t ideal, Sea’s three operating segments are growing like wildfire and paint the picture of a future mega-cap company.

At the moment, Sea’s gaming division, known as Garena, is the only one with positive earnings before interest, taxes, depreciation and amortization (EBITDA). What makes Garena so intriguing is that 11.8% of the company’s 654 million quarterly active users (QAUs) paid to play. The pay-to-play conversion rate for mobile games is typically under 10 figures. As long as Sea can sustain that level of engagement, mobile gaming should be a financial bright spot.

The second key segment is its SeaMoney financial services products. Since the emerging markets targeted by the sea in Southeast Asia and South America may not have access to basic banking services, the company’s digital wallet solutions can play an important role in democratizing finance for the booming middle classes in these regions. SeaMoney counted nearly 46 million QAU at the end of 2021.

But the segment that investors are most excited about is the Shopee e-commerce platform. In all of 2018, Shopee saw $10 billion in gross market value (GMV) flow through its platform. In the fourth quarter of 2021 alone, Sea recorded $18.2 billion in GMV through Shopee. Online ordering demand is skyrocketing in Southeast Asia and Brazil, which should help Sea expand its e-commerce operations over time and reduce losses.

Patient investors could see Sea Limited double its sales a few times over the next eight years.

10 Stocks We Like Better Than Teladoc Health
When our award-winning team of analysts have stock advice, it can pay to listen. After all, the newsletter they’ve been putting out for over a decade, Motley Fool Equity Advisortripled the market.*

They just revealed what they think are the ten best stocks investors can buy right now…and Teladoc Health wasn’t one of them! That’s right – they think these 10 stocks are even better buys.

View all 10 stocks

* Equity Advisor Returns as of April 7, 2022

Sean Williams owns Jushi Holdings and Teladoc Health. The Motley Fool owns and recommends Jushi Holdings, Sea Limited and Teladoc Health. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

If you have any query regarding content, please comment below. Thanks

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.



Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments